Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, director, Multiple Myeloma Program, professor of clinical medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab-tgvs (Talvey) in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study (NCT03399799/NCT04634552).